Posts Tagged ‘Biotech’
Novochizol’s AgrINovo Partnership: Swiss-Indian Alliance for Agricultural Innovation
Indian company Aquagri, its partner, and Novochizol SA, a Valais-based startup, announced the launch of AgrINovo, a transformative collaborative project. AgrINovo aims to unlock the full potential of Novochizol technology to foster a healthier, more sustainable agriculture in India and worldwide. Novochizol™ is derived from chitosan, made from chitin, the second most abundant polysaccharide…
Read MoreSwiss Health Valley Biotechs Advance Drug Pipelines with Promising Clinical Milestones
Three innovative biotech companies based in Western Switzerland, Stalicla, Legacy Healthcare and iOnctura, have recently achieved significant progress in their therapeutic pipelines, reinforcing the region’s position as a hub for health innovation. STALICLA: Advancing Precision Medicine for Autism Geneva-based STALICLA has received the green light from the U.S. Food and Drug Administration (FDA) to initiate…
Read MoreADM Opens R&D Center Dedicated to Animal Health and Wellness at Biopôle
Located ar Biopôle Lausanne in canton of Vaud, the new innovation hub will focus on advanced microbiome research for farm and companion animals ROLLE, Switzerland—ADM (NYSE: ADM), a global leader in innovative solutions from nature, has opened a new research and development (R&D) center focused on advancing research into animal microbiomes, and developing tailored…
Read MoreAzureCell Therapies secures CHF 150,000 from Venture Kick
AzureCell Therapies, a Biotech spin-off from the University of Geneva, has received CHF 150,000 from Venture Kick to deliver cell-based treatments that replace damaged neurons in Parkinson’s patients. Parkinson’s disease is an increasingly prevalent neurological disorder that affects over 10 million people worldwide. Current treatments only manage symptoms and fail to halt the disease’s…
Read Moreplanetary: The Only Swiss Finalist of the 2025 WIPO Global Awards
Out of 780 applications from 95 countries, planetary, a Geneva-Based startup specializing in sustainable food innovation, has been named the only Swiss finalist — and winner — of the 2025 WIPO Global Awards. This prestigious recognition by the World Intellectual Property Organization (WIPO) honors small and medium-sized enterprises (SMEs) leveraging intellectual property to tackle…
Read MoreBeech Biotech Awarded $1.9 million by the Gates Foundation
Beech Biotech, a Lausanne-based biopharmaceutical company creating “Mother only” monoclonals to treat complications of pregnancy, has been awarded a $1.9 million grant by the Gates Foundation for the development of its breakthrough therapeutic approach in preeclampsia. Preeclampsia is a leading cause worldwide of maternal morbidity and mortality, premature birth, stillbirth, and neonatal death. Each…
Read MoreHAYA Therapeutics Named a 2025 Technology Pioneer by the World Economic Forum
HAYA Therapeutics, a Biopôle Lausanne based startup has been selected as one of the 100 early-stage companies in the World Economic Forum’s 2025 Technology Pioneers cohort! This prestigious recognition highlights the company’s pioneering work in developing next-generation, disease-modifying precision medicines. HAYA is harnessing the power of the human genome’s dark matter to create precise RNA-based…
Read Moreten23 health Joins the “Alliance for RTU”
ten23 health joins the “Alliance for RTU” – an association to advance technical exchange for ready-to-use (RTU) containers in sterile manufacturing ten23 health, a CDTMO based in Basel and Visp,has joined the „Alliance for RTU“, an association to advance technical exchange for ready-to-use (RTU) containers in sterile manufacturing. The Alliance for RTU was formed…
Read MoreAzureCell Therapies Secures Innosuisse Grant to Advance Parkinson Disease Treatment
AzureCell Therapies, a University of Geneva spinoff at the forefront of regenerative medicine, has been awarded a CHF 650,000 grant from Innosuisse, Switzerland’s innovation agency, to advance its pioneering cell-replacement therapies for Parkinson’s disease. Rooted in over 20 years of research from the University of Geneva and backed by over CHF 8 million in…
Read MoreNewBiologix Licences Xcell-Eng-HEK293 Cell Line to Recipharm
NewBiologix, a Biopôle-based (Vaud)Swiss biotech innovator, has granted a non-exclusive licence to Recipharm Advanced Bio. The agreement gives Recipharm access to NewBiologix’s Xcell-Eng-HEK293 cell lines, enabling the efficient production of recombinant Adeno-Associated Viruses (rAAVs) for cell and gene therapies. The licensed cell lines offer high-yield, GMP-ready viral production, accelerating the path to clinical trials.…
Read More